255 related articles for article (PubMed ID: 15592670)
1. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
[TBL] [Abstract][Full Text] [Related]
2. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
4. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
6. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
Talmadge JE; Phillips H; Schindler J; Tribble H; Pennington R
Cancer Res; 1987 Nov; 47(21):5725-32. PubMed ID: 3499218
[TBL] [Abstract][Full Text] [Related]
7. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
Hinuma S; Naruo K; Shiho O; Tsukamoto K
Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
[TBL] [Abstract][Full Text] [Related]
9. Effect of albumin fusion on the biodistribution of interleukin-2.
Yao Z; Dai W; Perry J; Brechbiel MW; Sung C
Cancer Immunol Immunother; 2004 May; 53(5):404-10. PubMed ID: 14624312
[TBL] [Abstract][Full Text] [Related]
10. Preclinical approaches to the treatment of metastatic disease: therapeutic properties of rH TNF, rM IFN-gamma, and rH IL-2.
Talmadge JE; Black PL; Tribble H; Pennington R; Bowersox O; Schneider M; Phillips H
Drugs Exp Clin Res; 1987; 13(6):327-37. PubMed ID: 3115744
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses.
Brandes LJ; Arron RJ; Bogdanovic RP; Tong J; Zaborniak CL; Hogg GR; Warrington RC; Fang W; LaBella FS
Cancer Res; 1992 Jul; 52(13):3796-800. PubMed ID: 1617649
[TBL] [Abstract][Full Text] [Related]
12. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
Gately MK; Anderson TD; Hayes TJ
J Immunol; 1988 Jul; 141(1):189-200. PubMed ID: 3259967
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
14. Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma.
Bousquet PF; Paulsen LA; Fondy C; Lipski KM; Loucy KJ; Fondy TP
Cancer Res; 1990 Mar; 50(5):1431-9. PubMed ID: 2302708
[TBL] [Abstract][Full Text] [Related]
15. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265
[TBL] [Abstract][Full Text] [Related]
16. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases.
Sherwood ER; Williams DL; McNamee RB; Jones EL; Browder IW; Di Luzio NR
J Biol Response Mod; 1988 Apr; 7(2):185-98. PubMed ID: 3283299
[TBL] [Abstract][Full Text] [Related]
17. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
Naruo KI; Hinuma S; Shiho O; Houkan T; Ootsu K; Tsukamoto K
Clin Exp Immunol; 1989 May; 76(2):278-83. PubMed ID: 2788049
[TBL] [Abstract][Full Text] [Related]
18. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
19. Marked reduction of subcutaneous tumor growth by intraperitoneal administration of recombinant human interleukin 2 with a cell accumulator, proteose-peptone, in mice.
Tanida S; Uchida H; Taniguchi K; Nomoto K
Cancer Res; 1989 Jan; 49(2):284-8. PubMed ID: 2783379
[TBL] [Abstract][Full Text] [Related]
20. An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2.
Courtney LP; Phelps JL; Karavodin LM
Immunopharmacology; 1994; 28(3):223-32. PubMed ID: 7852053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
